R.D. Rahane, Punit R. Rachh
R.D. Rahane1*, Dr. Punit R. Rachh2
1Department of Pharmaceutics, Shri. Vivekanand Nursing Home Trust’s College of B. Pharmacy, Shrishivajinagar, Rahuri Factory, Dist - Ahmednagar, M.H., India.
2Department of Pharmaceutical Sciences, Bhagwant University, Ajmer, Rajasthan, India.
Volume - 13,
Issue - 11,
Year - 2020
Metformin and Glimepiride combinations are recently developed by various researches and Pharmaceutical industry. Hence it is needs to develop simple, precise, accurate, reliable and cost-effective method for Simultaneous determination of Metformin and Glimepiride. As per Pharmacopoeial recommendation pH 6.8 phosphate buffer is suitable dissolution method for combination of Metformin Hydrochloride and Glimepiride. In this study UV method is developed for simultaneous determination of Metformin Hydrochloride and Glimepiride. This involves measurement of absorption maxima at wavelength of about 226 nm and 233 nm for Glimepiride and Metformin Hydrochloride. In this study development and validation as per ICH Q2 (R1) is carried out. Various parameters such as Specificity, Solution Stability, Filter Compatibility, Filter Saturation, Linearity and Range, Precision, Accuracy were evaluated for validating developed method for determination of content of Metformin and Glimepiride.
Cite this article:
R.D. Rahane, Punit R. Rachh. Development and Validation of Simultaneous Estimation of Metformin Hydrochloride and Glimepiride in Physiological media. Research J. Pharm. and Tech. 2020; 13(11):5360-5364. doi: 10.5958/0974-360X.2020.00937.3
3. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F, Cellular and molecular mechanisms of metformin: an overview. Clinical Science (London). 2012;122(6);253-70.
4. US FDA prescribing information of Glocophage (Metformin hydrochloride) tablets, Bristol-Myers Squibb Company, USA; 2017
5. World Health Organization, Annexure 8 - Proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediate-release, solid oral dosage forms; WHO Technical Report Series, No. 937, 2006.
6. United States Pharmacopoeia, Metformin hydrochloride tablets monograph, 35th edition, The United States Pharmacopoeial Convention, 2012; 3879 – 3880.
7. Anthony, C, David, O, Brian, W, Clarke's Analysis of Drugs and Poisons, Pharmaceutical Press, 3rd edition; 2005.
8. European Medicine Compendia, Glucophage Film-Coated Tablets by Merck Serono Limited, 2019.
9. Maria L.A.D. Lestari, Gunawan Indrayanto, Glimepiride: An Overview; Profiles of Drug Substances, Excipients and Related Methodology, 2011.
10. John R. White, A Brief History of the Development of Diabetes Medication, Diabetes Spectrum, 2014, 27 (2).
11. US FDA prescribing information of AMARYL® (Glimepiride tablets) by Sanofi-aventis U.S. LLC, 2009.
12. Bhawandeep Gill, Tejvir Kaur, Sandeep Kumar, G D Gupta, Formulation and evaluation of Glimepiride solid dispersion tablets, Asian Journal of Pharmaceutics, 2010, 212 – 218.
13. United States Pharmacopoeia, Glimepiride tablets monograph, 33th edition, The United States Pharmacopoeial Convention, 2010.
14. European Medicine Compendia, Glimepiride 1 mg Tablets by Accord Healthcare Limited, United Kingdom, 2014.
15. European Medicine Agency, Glimepiride - Assessment report, Procedure no: EMEA/H/A-29/1338, 2012.
16. Audumbar Digambar Mali, Seeta Mali, Ashpak Tamboli, Ritesh Bathe, ‘Simultaneous UV Spectrophotometric Methods for Estimation of Metformin HCl and Glimepiride in Bulk and Tablet Dosage Form’, International Journal of Advances in Pharmaceutics, 4 (6); 2015.
17. ICH Harmonized Tripartite Guideline Q2 (R1), Validation of Analytical Procedure, 2003.